Shilpa Medicare Limited (BOM:530549)
278.55
-11.40 (-3.93%)
At close: Jan 20, 2026
Shilpa Medicare Employees
Shilpa Medicare had 998 employees as of March 31, 2025. The number of employees decreased by 9 or -0.89% compared to the previous year.
Employees
998
Change (1Y)
-9
Growth (1Y)
-0.89%
Revenue / Employee
13.46M INR
Profits / Employee
1.38M INR
Market Cap
52.93B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 998 | -9 | -0.89% |
| Mar 31, 2024 | 1,007 | -172 | -14.59% |
| Mar 31, 2023 | 1,179 | -1,703 | -59.09% |
| Mar 31, 2022 | 2,882 | 388 | 15.56% |
| Mar 31, 2021 | 2,494 | 479 | 23.77% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| IOL Chemicals and Pharmaceuticals | 2,891 |
| Neuland Laboratories | 1,794 |
| Bajaj HealthCare | 918 |
| NGL Fine-Chem | 520 |
| Sudeep Pharma | 480 |
| Gujarat Themis Biosyn | 221 |
| Influx Healthtech | 163 |
| Shree Ganesh Remedies | 149 |
Shilpa Medicare News
- 6 weeks ago - Shilpa Medicare receives Initial Authorization for Rotigotine transdermal patch in European - Business Upturn
- 2 months ago - Shilpa Medicare Ltd (BOM:530549) Q2 2026 Earnings Call Highlights: Record EBITDA and Strategic ... - GuruFocus
- 2 months ago - Q2 2026 Shilpa Medicare Ltd Earnings Call Transcript - GuruFocus
- 2 months ago - Shilpa Medicare launches world’s first NODUCA Therapy for MAFLD after CDSCO approval - Business Upturn
- 2 months ago - Shilpa Medicare Q2 Results: Net profit jumps 144% YoY to Rs 44 crore, revenue up 7.6% - Business Upturn
- 2 months ago - Shilpa Medicare shares jump nearly 3% after positive Phase 3 results for once-weekly Ondansetron injection OERIS™ - Business Upturn
- 2 months ago - Shilpa Medicare announces positive Phase 3 results for OERIS™ — once-weekly Ondansetron injection for chemotherapy-induced nausea and vomiting - Business Upturn
- 2 months ago - Shilpa Pharma Lifesciences wins EcoVadis Gold Medal for excellence in sustainability - Business Upturn